Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
US pharma behemoth Pfizer (NYSE: PFE) has launched a pre-emptive strike against generic drug manufacturer Mylan (Nasdaq; MYL) to protect its smoking cessation drug Chantix (varenicline), according to a report by The Street.Com.
In a complaint filed in Manhattan federal court on August 30, Pfizer accused Mylan of infringing on two patents the company holds that it believes cover Chantix. According to the complaint, Mylan recently filed an abbreviated new drug application with the Food and Drug Administration to market a generic version of Chantix.
Pfizer, which maintains its patents on Chantix run until 2020, alleges violations on two counts of patent infringement and is seeking to block any sales of the generic as well as unspecified damages, says The Street.com. The drug generated $700 million in revenue for the company in 2009, down from $883 million in 2007.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze